Teva Pharmaceutical Industries Ltd
TASE:TEVA

Watchlist Manager
Teva Pharmaceutical Industries Ltd Logo
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Watchlist
Price: 6 340 ILS 0.32% Market Closed
Market Cap: 71.4B ILS
Have any thoughts about
Teva Pharmaceutical Industries Ltd?
Write Note

Operating Margin
Teva Pharmaceutical Industries Ltd

22.8%
Current
21%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
22.8%
=
Operating Profit
3.7B
/
Revenue
16.3B

Operating Margin Across Competitors

Country IL
Market Cap 71.4B ILS
Operating Margin
23%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 710.5B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 373.5B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 202.7B CHF
Operating Margin
32%
Country CH
Market Cap 183.3B CHF
Operating Margin
31%
Country UK
Market Cap 162.4B GBP
Operating Margin
21%
Country IE
Market Cap 146B USD
Operating Margin
11%
No Stocks Found

Teva Pharmaceutical Industries Ltd
Glance View

Market Cap
71.4B ILS
Industry
Pharmaceuticals

Teva Pharmaceutical Industries Ltd., a pivotal player in the global pharmaceutical landscape, has carved out its niche as one of the world's largest generic drug manufacturers. Founded in 1901 and headquartered in Petah Tikva, Israel, Teva has grown through a series of strategic acquisitions and robust research and development initiatives, thereby establishing a diverse portfolio that includes both generic medications and innovative biopharmaceuticals. The company is particularly known for its vast offerings in pain management, central nervous system disorders, and respiratory therapies, positioning itself as a vital resource for accessible healthcare solutions around the globe. With operations in over 60 countries and a commitment to providing affordable medications, Teva plays a significant role in expanding the reach of essential treatments, driving patient adherence and improving health outcomes. However, Teva's journey has not been without challenges. The company has faced various headwinds, including increasing competition in the generic market, pricing pressures, and legal battles related to opioid litigations. Investors should note that Teva is currently focused on restructuring efforts to enhance operational efficiency and strengthen its balance sheet. While navigating these complexities, the company also invests in innovative drug development, aiming to diversify its pipeline and capitalize on high-growth therapeutic areas. Teva's forward-looking strategies offer an intriguing investment proposition, as they combine the potential for stability through generics with the growth opportunities found in its specialty pharmaceuticals, making it a compelling option for those looking to invest in the evolving pharmaceutical sector.

TEVA Intrinsic Value
5 820.65 ILS
Overvaluation 8%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
22.8%
=
Operating Profit
3.7B
/
Revenue
16.3B
What is the Operating Margin of Teva Pharmaceutical Industries Ltd?

Based on Teva Pharmaceutical Industries Ltd's most recent financial statements, the company has Operating Margin of 22.8%.